8-K: Waystar Reports Strong Q2 2025 Results, Raises Full-Year Guidance Amid Strategic Acquisition

Waystar Holding Corp. announced robust second-quarter 2025 financial results, including 15% revenue growth and increased full-year revenue and adjusted EBITDA guidance, alongside an agreement to acquire Iodine Software.

Summary

• Q2 2025 revenue reached $270.7 million, marking a 15% increase year-over-year.
• GAAP net income for Q2 2025 was $32.2 million, resulting in a net income margin of 12%.
• Non-GAAP net income for Q2 2025 stood at $65.7 million.
• Adjusted EBITDA for Q2 2025 was $112.6 million, with an adjusted EBITDA margin of 42%.
• Cash flow from operations for the six months ended June 30, 2025, was $97 million.
• Unlevered free cash flow for the six months ended June 30, 2025, was $111 million.
• The number of clients contributing over $100,000 in last twelve months (LTM) revenue increased by 14% year-over-year to 1,268.
• The Net Revenue Retention Rate (NRR) was 115%.
• Subscription revenue grew 17% year-over-year to $131.1 million in Q2 2025.
• Volume-based revenue increased 14% year-over-year to $138.3 million in Q2 2025.
• The company announced an agreement to acquire Iodine Software, an AI-powered clinical intelligence leader, which is expected to expand Waystar's total addressable market and be accretive to its financial profile.
• Full fiscal year 2025 total revenue guidance was raised to a range of $1.030 billion to $1.042 billion.
• Full fiscal year 2025 adjusted EBITDA guidance was raised to a range of $418 million to $426 million.
• Full fiscal year 2025 non-GAAP net income is expected to be between $251 million and $257 million.
• Full fiscal year 2025 diluted non-GAAP net income per share is projected to be between $1.36 and $1.40.

Sentiment

Score: 9

Explanation: The filing reports strong financial performance with significant year-over-year growth in key metrics, a return to profitability, improved margins, and robust cash flow. The company also raised its full-year guidance and announced a strategic acquisition expected to be accretive, indicating strong momentum and positive future prospects.

Positives

• Revenue grew by a strong 15% year-over-year in Q2 2025, reaching $270.7 million.
• Achieved a GAAP net income of $32.2 million in Q2 2025, a significant turnaround from a net loss of $(27.685) million in Q2 2024.
• Adjusted EBITDA margin improved to 41.6% in Q2 2025 from 40.0% in Q2 2024, demonstrating enhanced profitability.
• Generated robust cash flow from operations of $97 million and unlevered free cash flow of $111 million in Q2 2025.
• Increased the number of clients contributing over $100,000 in LTM revenue by 14% year-over-year, indicating strong client acquisition and retention.
• Maintained a high Net Revenue Retention Rate (NRR) of 115%, reflecting strong client satisfaction and upsell capabilities.
• Both subscription revenue (up 17% YOY) and volume-based revenue (up 14% YOY) showed healthy growth.
• Raised full-year 2025 revenue and adjusted EBITDA guidance, signaling confidence in continued strong performance.
• The announced acquisition of Iodine Software is expected to expand the total addressable market and be financially accretive.
• Income from operations significantly increased to $64.846 million in Q2 2025 from $8.245 million in Q2 2024.
• Interest expense decreased substantially to $(17.325) million in Q2 2025 from $(49.195) million in Q2 2024.
• Cash and cash equivalents increased to $290.3 million at June 30, 2025, from $182.133 million at December 31, 2024.
• Net debt decreased to $896.919 million at June 30, 2025, from $1,292.525 million at June 30, 2024.
• Adjusted Net leverage ratio improved to 2.2x at June 30, 2025, from 3.7x at June 30, 2024.

Risks

• Operating in a highly competitive industry.
• Ability to retain existing clients and attract new clients.
• Ability to successfully execute on business strategies for growth.
• Ability to accurately assess risks related to acquisitions and successfully integrate acquired businesses, including Iodine Software.
• Ability to establish and maintain strategic relationships.
• Growth and success of clients and overall healthcare transaction volumes.
• Consolidation in the healthcare industry.
• Selling cycle of variable length to secure new client agreements.
• Implementation cycle dependent on client timing and resources.
• Dependence on senior management team and certain key employees, and ability to attract and retain highly skilled employees.
• Accuracy of estimates and assumptions used to determine the size of the total addressable market.
• Ability to develop and market new solutions, or enhance existing solutions, to respond to technological changes or evolving industry standards.
• Interoperability, connectivity, and integration of solutions with client and vendor networks and infrastructures.
• Performance and reliability of internet, mobile, and other infrastructure.
• Consequences if unable to obtain, process, use, disclose, or distribute the highly regulated data required to provide solutions.
• Reliance on certain third-party vendors and providers.
• Any errors or malfunctions in products and solutions.
• Failure by clients to obtain proper permissions or provide accurate and appropriate information.
• Potential for embezzlement, identity theft, or other similar illegal behavior by employees or vendors, and a failure of employees or vendors to observe quality standards or adhere to environmental, social, and governance standards.
• Compliance with the applicable rules of the National Automated Clearing House Association and the applicable requirements of card networks.
• Increases in card network fees and other changes to fee arrangements.
• The effect of payer and provider conduct which cannot be controlled.
• Privacy concerns and security breaches or incidents relating to the platform.
• The complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity.
• Ability to adequately protect and enforce intellectual property rights.
• Ability to use or license data and integrate third-party technologies.
• Use of open source software.
• Legal proceedings initiated by third parties alleging infringement or other violation of their intellectual property rights.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.
• Operating in a heavily regulated industry.
• The uncertain and evolving healthcare regulatory and political framework.
• Healthcare laws and data privacy and security laws and regulations governing the processing of personal information.
• Reduced revenues in response to changes to the healthcare regulatory landscape.
• Legal, regulatory, and other proceedings that could result in adverse outcomes.
• Consumer protection laws and regulations.
• Contractual obligations requiring compliance with certain provisions of the Bank Secrecy Act and anti-money laundering laws and regulations.
• Existing laws that regulate the ability to engage in certain marketing activities.
• Full compliance with website accessibility standards.
• Any changes in tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities.
• Limitations on the ability to use net operating losses to offset future taxable income.
• Losses due to asset impairment charges.
• Restrictive covenants in the agreements governing credit facilities.
• Interest rate fluctuations.
• Unavailability of additional capital on acceptable terms or at all.
• The impact of general macroeconomic conditions.
• Actions of certain significant investors, who may have different interests than other holders of securities.
• Status as an 'emerging growth company' and whether the reduced disclosure requirements applicable will make common stock less attractive to investors.

Future Outlook

Waystar raised its full fiscal year 2025 guidance, expecting total revenue between $1.030 billion and $1.042 billion, adjusted EBITDA between $418 million and $426 million, non-GAAP net income between $251 million and $257 million, and diluted non-GAAP net income per share between $1.36 and $1.40. This guidance excludes the impact of the previously announced acquisition of Iodine Software.

Management Comments

• "Waystar recorded strong Q2 results, including 15% revenue growth, driven by AI-powered innovations, trusted client relationships, and compelling and real ROI for healthcare providers."
• "Our execution and momentum enable us to raise full-year revenue and adjusted EBITDA guidance."
• "Waystar also recently announced an agreement to acquire Iodine Software, a leader in AI-powered clinical intelligence, which we expect will expand our total addressable market, be accretive to our financial profile, and position us to deliver even greater value to clients and shareholders."

Industry Context

Waystar operates in the healthcare payment software industry, providing mission-critical solutions to simplify healthcare payments. The company's focus on AI-powered innovations and expanding its total addressable market through acquisitions like Iodine Software aligns with broader industry trends towards technological advancement and consolidation to enhance efficiency and value for healthcare providers. The strong revenue growth and high net revenue retention rate suggest a robust position within this competitive sector, driven by the demand for solutions that offer clear ROI for providers.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, raised guidance, and strategic acquisition, potentially leading to increased share value.
• Clients (Healthcare Providers): Continued value delivery through AI-powered innovations and expanded offerings from the Iodine Software acquisition, simplifying healthcare payments and optimizing financial performance.
• Employees: Continued growth and strategic expansion may lead to job stability and potential opportunities.
• Creditors: Improved financial health, reduced net debt, and better leverage ratios enhance the company's creditworthiness.

Next Steps

• A conference call to discuss financial results is scheduled for July 30, 2025, at 4:30 p.m. Eastern Daylight Time.
• Integration of the Iodine Software acquisition is expected to expand the total addressable market and be accretive to the financial profile.
• Investors should monitor the Investor Relations section of Waystar's website for material, non-public information and compliance with Regulation FD.

Key Dates

Recommendation

The company demonstrated exceptional financial performance in Q2 2025, marked by significant revenue growth, a strong return to GAAP net income, and robust cash flow generation. The substantial improvement in net income from a loss in the prior year, coupled with improved adjusted EBITDA margins, indicates strong operational efficiency and profitability. The decision to raise full-year guidance for both revenue and adjusted EBITDA signals management's confidence in continued momentum. Furthermore, the strategic acquisition of Iodine Software is expected to expand the total addressable market and be financially accretive, positioning the company for sustained long-term growth. The significant reduction in net debt and improvement in the adjusted net leverage ratio also strengthen the balance sheet. These factors collectively present a highly compelling investment case.

Keywords

Healthcare payment software, Revenue cycle management, RCM, Healthcare technology, Health tech, AI, Artificial intelligence, Financial results, Earnings, Q2 2025, Waystar, Iodine Software, Acquisition, EBITDA, Net income, Cash flow, NRR, Software as a Service, SaaS